23.03.2015 • News

Oschmann Set to Become Merck KGaA's CEO

Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to replace current CEO Karl-Ludwig Kley next year, Manager Magazin reported on Friday.

Oschmann, 57, would take on the new role next year after the group's annual shareholder meeting in April 2016 or in September next year at the latest, when Kley's current contract expires.

The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January 2015 on, sharing strategic management functions and representation of the company with Kley (63).

A Merck spokeswoman said a decision on Kley's succession has not yet been made and that this would be a matter for the family-controlled group's board of partners.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read